MY197236A - 2'-substituted-n6-substituted purine nucleotides for rna virus treatment - Google Patents

2'-substituted-n6-substituted purine nucleotides for rna virus treatment

Info

Publication number
MY197236A
MY197236A MYPI2019001191A MYPI2019001191A MY197236A MY 197236 A MY197236 A MY 197236A MY PI2019001191 A MYPI2019001191 A MY PI2019001191A MY PI2019001191 A MYPI2019001191 A MY PI2019001191A MY 197236 A MY197236 A MY 197236A
Authority
MY
Malaysia
Prior art keywords
substituted
rna virus
purine nucleotides
virus treatment
treatment
Prior art date
Application number
MYPI2019001191A
Other languages
English (en)
Inventor
Sommadossi Jean-Pierre
Moussa Adel
Original Assignee
Atea Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atea Pharmaceuticals Inc filed Critical Atea Pharmaceuticals Inc
Publication of MY197236A publication Critical patent/MY197236A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI2019001191A 2016-09-07 2017-09-06 2'-substituted-n6-substituted purine nucleotides for rna virus treatment MY197236A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384664P 2016-09-07 2016-09-07
PCT/US2017/050323 WO2018048937A1 (en) 2016-09-07 2017-09-06 2'-substituted-n6-substituted purine nucleotides for rna virus treatment

Publications (1)

Publication Number Publication Date
MY197236A true MY197236A (en) 2023-06-07

Family

ID=61562513

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001191A MY197236A (en) 2016-09-07 2017-09-06 2'-substituted-n6-substituted purine nucleotides for rna virus treatment

Country Status (24)

Country Link
US (3) US10946033B2 (OSRAM)
EP (3) EP3512863B1 (OSRAM)
JP (4) JP2019526596A (OSRAM)
KR (3) KR20220146668A (OSRAM)
CN (2) CN109689672B (OSRAM)
AU (3) AU2017324939B2 (OSRAM)
BR (1) BR112019004297A2 (OSRAM)
CA (2) CA3034648C (OSRAM)
CY (1) CY1125163T1 (OSRAM)
DK (1) DK3512863T3 (OSRAM)
EA (2) EA037868B1 (OSRAM)
ES (1) ES2907874T3 (OSRAM)
HR (1) HRP20220278T1 (OSRAM)
HU (1) HUE057743T2 (OSRAM)
LT (1) LT3512863T (OSRAM)
MY (1) MY197236A (OSRAM)
PL (1) PL3512863T3 (OSRAM)
PT (1) PT3512863T (OSRAM)
RS (1) RS62943B1 (OSRAM)
SG (1) SG11201901457TA (OSRAM)
SI (1) SI3512863T1 (OSRAM)
SM (1) SMT202200072T1 (OSRAM)
WO (1) WO2018048937A1 (OSRAM)
ZA (2) ZA201901061B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
ES2907874T3 (es) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
CN111087421B (zh) * 2019-12-24 2022-10-18 南京正大天晴制药有限公司 一种用于手性药物合成的磷酰胺化合物的制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2021253376A1 (zh) * 2020-06-19 2021-12-23 南京正大天晴制药有限公司 一种用于手性药物合成的磷酰胺化合物的制备方法
TW202214260A (zh) * 2020-08-19 2022-04-16 美商亞堤製藥公司 立體選擇性製造選定的嘌呤胺基磷酸酯
WO2022076903A1 (en) * 2020-10-09 2022-04-14 Atea Pharmaceuticals, Inc. Niran interfering drugs for sars-cov-2 mutant therapy
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN116744939A (zh) 2021-01-26 2023-09-12 阿堤亚制药公司 At-527半硫酸盐的有利形态
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
JP2024533122A (ja) * 2021-09-03 2024-09-12 アテア ファーマシューティカルズ， インコーポレイテッド フラビウイルス治療用の２’－クロロ－２’－フルオロ－ｎ２－アミノ－ｎ６－メチルアミノプリンヌクレオチド
WO2023034617A1 (en) * 2021-09-03 2023-03-09 Atea Pharmaceuticals, Inc. 2'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatment
CN115232165A (zh) * 2022-08-09 2022-10-25 安徽一灵药业有限公司 索非布韦中间体的合成方法
WO2025014360A1 (en) 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US900629A (en) 1906-02-15 1908-10-06 Robert Wettel Combination latch and key lock.
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
DE9314572U1 (de) 1993-09-27 1995-02-02 Dr. Hahn GmbH & Co. KG., 41189 Mönchengladbach Band für Türen, Fenster u.dgl.
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
EP0834270B1 (de) 1996-10-07 2003-07-30 Julius Blum Gesellschaft m.b.H. Ausziehführungsgarnitur für Schubladen
JP2001524936A (ja) 1996-10-16 2001-12-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド プリンｌ―ヌクレオシド類およびその用途
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
MXPA00008348A (es) 1998-02-25 2005-07-15 Univ Emory 2-fluronucleosidos.
CA2352749A1 (en) 1998-11-30 2000-06-08 Novozymes A/S Anti-dandruff composition comprising an antifungal polypeptide
DE60002986T2 (de) 1999-02-12 2004-05-19 Glaxo Group Ltd., Greenford Phosphoramidat-, mono-, di-, und triphosphatester von (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol als antivirale mittel
IN191496B (OSRAM) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AU785355B2 (en) 1999-12-03 2007-02-01 Regents Of The University Of California At San Diego, The Phosphonate compounds
WO2001079246A2 (en) 2000-04-13 2001-10-25 Pharmasset, Ltd. 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
EP2180064A3 (en) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
US20030087873A1 (en) 2000-10-18 2003-05-08 Lieven Stuyver Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
AU2002322325A1 (en) 2001-06-22 2003-01-08 Emory University Beta-2'-or 3'-halonucleosides
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
JP2005519916A (ja) 2001-12-14 2005-07-07 フアーマセツト・リミテツド ウィルス感染治療用ｎ４−アシルシトシンヌクレオシド類
EP1569658A4 (en) 2001-12-20 2007-05-30 Pharmassett Ltd TREATMENT OF EBV AND KHSV INFECTION AND AN ASSOCIATED ABNORMAL CELL PROLIFERATION
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US7323453B2 (en) 2002-02-13 2008-01-29 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
NZ536123A (en) 2002-05-06 2006-09-29 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
CA2488484A1 (en) 2002-06-27 2004-01-08 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
AP2005003211A0 (en) 2002-06-28 2005-03-31 Idenix Cayman Ltd 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
MY140819A (en) * 2002-06-28 2010-01-29 Idenix Caymans Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
BR0312278A (pt) 2002-06-28 2007-06-19 Idenix Cayman Ltd éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
US7323449B2 (en) 2002-07-24 2008-01-29 Merck & Co., Inc. Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
SG174624A1 (en) 2002-08-01 2011-10-28 Pharmasset Inc Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
WO2004014312A2 (en) 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
NZ540913A (en) 2002-12-23 2008-02-29 Idenix Cayman Ltd Process for the production of 3'-nucleoside prodrugs
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
CN1777432B (zh) 2003-02-19 2011-06-08 耶鲁大学 用于hiv感染的抗病毒核苷类似物
US20050020675A1 (en) 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) * 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
DE602004003389T2 (de) 2003-06-19 2007-09-13 F. Hoffmann-La Roche Ag Verfahren zur herstellung von 4'-azidonukleosidderivaten
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
BRPI0412849A (pt) 2003-07-25 2006-09-26 Idenix Cayman Ltd compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
DE10335061B4 (de) 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
CA2537114C (en) 2003-08-27 2012-10-02 Biota, Inc. Tricyclic nucleosides or nucleotides as therapeutic agents
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
WO2006012078A2 (en) 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
CA2572583A1 (en) 2004-06-29 2006-01-12 Avery Dennison Corporation Nonwoven-elastomeric laminate with improved bonding between elastomer and nonwoven web
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
PT3109244T (pt) 2004-09-14 2019-06-04 Gilead Pharmasset Llc ¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
EP1814561A4 (en) 2004-10-29 2012-12-19 Biocryst Pharm Inc THEROPUTICAL FUROPYRIMIDINES AND THIENOPYRIMIDINES
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
JP2008523098A (ja) 2004-12-10 2008-07-03 エモリー・ユニバーシテイ ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
AU2006222563A1 (en) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006102533A2 (en) 2005-03-23 2006-09-28 Neopharm, Inc. Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
WO2006104945A2 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis c therapies
WO2006130217A2 (en) 2005-04-01 2006-12-07 The Regents Of The University Of California Substituted phosphate esters of nucleoside phosphonates
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
AU2006280175B2 (en) 2005-08-09 2011-09-01 Merck Sharp & Dohme Corp. Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection
CA2618713A1 (en) 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
US7888330B2 (en) 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
WO2007095269A2 (en) 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2600792T3 (es) 2006-05-03 2017-02-10 Chimerix, Inc. Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
DK2084174T3 (da) 2006-10-10 2013-11-04 Gilead Pharmasset Llc Fremstilling af ribofuranosylpyrimidinnukleotider
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
EP2120565B1 (en) 2006-12-20 2012-11-28 Merck Sharp & Dohme Corp. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
AU2007342367B2 (en) 2007-01-05 2012-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
WO2008089105A2 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
JP2010518015A (ja) 2007-01-31 2010-05-27 アリオス バイオファーマ インク． ２−５ａアナログ類およびそれらの使用方法
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
AU2012241173B2 (en) * 2007-03-30 2014-09-25 Gilead Sciences, Inc. Nucleoside Phosphoramidate Prodrugs
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP1980568A1 (de) 2007-04-13 2008-10-15 Eberhard Karls Universität Tübingen Ethinylierte Heterodinucleosidphosphatanaloga, Verfahren zu deren Herstellung und deren Verwendung
PL2155758T3 (pl) 2007-05-10 2013-06-28 Biocryst Pharm Inc Pochodne tetrahydrofuro[3,4-d]dioksolanu przeznaczone do stosowania w leczeniu infekcji wirusowych i raka
CA2685748A1 (en) 2007-05-14 2008-11-14 Rfs Pharma, Llc. Azido purine nucleosides for treatment of viral infections
PL2014771T3 (pl) 2007-06-25 2015-05-29 Anadys Pharmaceuticals Inc Ciągły proces hydrolizy enzymatycznej
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20090060872A1 (en) 2007-08-31 2009-03-05 Idenix Pharmaceuticals, Inc. Phosphadiazine hcv polymerase inhibitors v
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US20090181921A1 (en) 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP3042660A3 (en) 2008-04-15 2016-10-26 RFS Pharma, LLC. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
SI2268642T1 (sl) 2008-04-23 2015-05-29 Gilead Sciences, Inc. 1'-substituirani karba-nukleozidni analogi za antivirusno zdravljenje
US8173621B2 (en) * 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AR072428A1 (es) 2008-07-01 2010-08-25 Medivir Ab Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos.
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8736709B2 (en) 2008-07-11 2014-05-27 The Invention Science Fund I, Llc Spectral improvement of digital camera color images
TW201019939A (en) 2008-08-20 2010-06-01 Schering Corp Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
TW201020238A (en) 2008-08-20 2010-06-01 Schering Corp Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5674661B2 (ja) 2008-08-20 2015-02-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． エチニル置換ピリジンおよびピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
JP5731976B2 (ja) 2008-08-20 2015-06-10 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
WO2010068708A2 (en) * 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
BRPI1004575A2 (pt) 2009-01-09 2016-04-05 Inhibitex Inc composto, composição farmacêutica, método de tratamento de infecções virais, método de separação dos diaestereômeros de fósforo
CA2751458C (en) * 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
PL2396340T3 (pl) 2009-02-10 2014-05-30 Gilead Sciences Inc Analogi karba-nukleozydu do terapii przeciwwirusowych
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
EP2408306A4 (en) 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
WO2010108135A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2483288B1 (en) 2009-09-29 2016-11-16 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
CN102725302B (zh) 2009-11-16 2016-04-06 乔治亚大学研究基金公司 2＇-氟-6＇-亚甲基碳环核苷和治疗病毒感染的方法
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
US8333309B2 (en) 2010-03-02 2012-12-18 Kenneth Riddleberger Hunter's adjustable encapsulating scent adsorption system with combination pack and detachably securable flexible funnel for human odor adsorption
ES2644990T3 (es) 2010-03-31 2017-12-01 Gilead Pharmasset Llc Síntesis estereoselectiva de principios activos que contienen fósforo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
CA2795054A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2011130557A2 (en) 2010-04-14 2011-10-20 The Regents Of The University Of California Phosphonates with reduced toxicity for treatment of viral infections
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en) 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8859595B2 (en) 2010-08-26 2014-10-14 Rfs Pharma, Llc Potent and selective inhibitors of hepatitis C virus
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
ES2701020T3 (es) 2010-09-22 2019-02-20 Alios Biopharma Inc Nucleósidos azido y análogos nucleotídicos
SG188497A1 (en) 2010-09-22 2013-05-31 Alios Biopharma Inc Substituted nucleotide analogs
WO2012041965A1 (en) 2010-09-29 2012-04-05 Universidad Nacional De Quilmes Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
EP2638054B1 (en) 2010-11-10 2014-12-03 Janssen Products, L.P. Uracyl spirooxetane nucleoside phosphoramidates
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
CN103403014B (zh) 2011-01-03 2016-07-06 河南美泰宝生物制药有限公司 O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
MX339822B (es) 2011-03-01 2016-06-13 Nucana Biomed Ltd Derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento contra el cancer.
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
US9061041B2 (en) 2011-04-13 2015-06-23 Merck Sharp & Dohme Corp. 2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012142075A1 (en) * 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
ES2744587T3 (es) 2011-04-13 2020-02-25 Gilead Sciences Inc Análogos de N-nucleósido de pirimidina 1-sustituidos para un tratamiento antiviral
RU2013125713A (ru) 2011-05-19 2015-06-27 Рфс Фарма, Ллк Пуринмонофосфатные пролекарства для лечения вирусных инфекций
CN103796648B (zh) * 2011-07-12 2019-10-25 范德比尔特大学 用γ-醛酮清除剂治疗炎症和高血压的方法
WO2013009737A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
AU2012290089B2 (en) 2011-08-01 2016-09-29 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
WO2013039855A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
US8575119B2 (en) 2011-09-23 2013-11-05 Enanta Pharmaceuticals, Inc. 2′-chloroacetylenyl substituted nucleoside derivatives
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013059735A1 (en) 2011-10-19 2013-04-25 Mercator Medsystems, Inc. Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
GB2497580A (en) 2011-12-16 2013-06-19 Intercede Ltd Data transmission using a plurality of barcodes displayed in a loop
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
SG11201404706XA (en) 2012-02-14 2014-09-26 Univ Georgia Spiro [2.4]heptanes for treatment of flaviviridae infections
MX352171B (es) 2012-02-27 2017-11-13 Bristol Myers Squibb Co Sal de hemisulfato de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6 ,7,8,9-tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3-dihid ro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1-carboxilato.
WO2013142125A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CN103421068A (zh) * 2012-05-17 2013-12-04 世方药业（杭州）有限公司 具有抗病毒活性的杂芳基磷酰胺类化合物
US8846638B2 (en) 2012-05-17 2014-09-30 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
WO2013187978A1 (en) 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN104583224A (zh) 2012-07-03 2015-04-29 百时美施贵宝公司 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
US9326991B2 (en) 2012-09-14 2016-05-03 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds and use
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AU2013329521B2 (en) 2012-10-08 2018-04-19 Centre National De La Recherche Scientifique 2'-chloro nucleoside analogs for HCV infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
BR112015009636A8 (pt) 2012-10-29 2018-04-17 Cocrystal Pharma Inc composto, métodos para o tratamento de um hospedeiro infectado, métodos para a prevenção de uma infecção, métodos para a redução da atividade biológica de uma infecção e uso de um composto
PT3235824T (pt) 2012-11-16 2019-05-30 NuCana plc Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
US9211300B2 (en) * 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
KR102788773B1 (ko) 2012-12-21 2025-03-28 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
HK1216535A1 (zh) 2012-12-21 2016-11-18 Alios Biopharma, Inc. 取代的核苷、核苷酸及其類似物
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
MX374244B (es) * 2013-03-08 2025-03-05 Nanjing Sanhome Pharmaceutical Co Ltd Compuesto de fosforamidato de nucleosido novedoso y su uso.
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
JP2016522172A (ja) 2013-04-12 2016-07-28 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｈｃｖを治療するのに有用な重水素化されたヌクレオシドプロドラッグ
CN103435672A (zh) 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
KR102314960B1 (ko) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
MX2016006919A (es) 2013-11-27 2016-08-17 Idenix Pharmaceuticals Llc Nucleotidos para el tratamiento de cancer de higado.
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015095305A1 (en) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
US20170022242A1 (en) 2014-04-17 2017-01-26 Katholieke Universiteit Leuven, KU LEUVEN R&D Novel antiviral and antitumoral compounds
EP3160475B1 (en) 2014-06-24 2024-01-03 Janssen Pharmaceuticals, Inc. Substituted nucleosides and nucleotides to treat filoviridae infections
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2016041877A1 (en) 2014-09-15 2016-03-24 Medivir Ab Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
AU2016229966B2 (en) 2015-03-06 2018-09-27 Atea Pharmaceuticals, Inc. Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN106188192B (zh) 2015-04-29 2019-09-10 刘沛 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
CN106366146A (zh) 2015-07-13 2017-02-01 中科云和（北京）生物医药科技有限公司 2’-双烷基取代的核苷类似物及用途
KR102000100B1 (ko) * 2016-03-23 2019-07-16 주식회사 엘지화학 비수전해액 첨가제, 이를 포함하는 리튬 이차전지용 비수전해액 및 리튬 이차전지
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
ES2907874T3 (es) 2016-09-07 2022-04-26 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-sustituidos-N6-sustituidos para el tratamiento de virus de ARN
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis

Also Published As

Publication number Publication date
AU2017324939A1 (en) 2019-03-21
SMT202200072T1 (it) 2022-03-21
ZA202106848B (en) 2025-01-29
US20200222442A1 (en) 2020-07-16
KR102456417B1 (ko) 2022-10-19
JP2023171730A (ja) 2023-12-05
WO2018048937A1 (en) 2018-03-15
KR20220146668A (ko) 2022-11-01
LT3512863T (lt) 2022-03-10
US11975016B2 (en) 2024-05-07
CA3034648A1 (en) 2018-03-15
AU2022215185A1 (en) 2022-09-01
JP7124024B2 (ja) 2022-08-23
EA202190602A2 (ru) 2021-06-30
PL3512863T3 (pl) 2022-04-04
KR20190043602A (ko) 2019-04-26
CA3187650A1 (en) 2018-03-15
EA201990628A1 (ru) 2019-09-30
JP2019526596A (ja) 2019-09-19
AU2017324939B2 (en) 2021-10-14
RU2019109263A (ru) 2020-10-08
EA202190602A3 (ru) 2021-11-30
ZA201901061B (en) 2021-06-30
HRP20220278T1 (hr) 2022-05-13
EP3512863A1 (en) 2019-07-24
EP3865136A1 (en) 2021-08-18
EP3512863B1 (en) 2021-12-08
CA3034648C (en) 2023-02-28
CN116036114A (zh) 2023-05-02
JP2021001202A (ja) 2021-01-07
SI3512863T1 (sl) 2022-04-29
DK3512863T3 (da) 2022-03-07
HUE057743T2 (hu) 2022-06-28
SG11201901457TA (en) 2019-03-28
AU2020220216B2 (en) 2022-05-19
JP2022068329A (ja) 2022-05-09
CY1125163T1 (el) 2023-06-09
EA037868B1 (ru) 2021-05-28
BR112019004297A2 (pt) 2019-05-28
ES2907874T3 (es) 2022-04-26
US10946033B2 (en) 2021-03-16
RS62943B1 (sr) 2022-03-31
US20190201433A1 (en) 2019-07-04
EP3512863A4 (en) 2020-06-03
CN109689672A (zh) 2019-04-26
KR20200106561A (ko) 2020-09-14
PT3512863T (pt) 2022-03-09
CN109689672B (zh) 2023-05-30
AU2020220216A1 (en) 2020-09-10
RU2019109263A3 (OSRAM) 2020-12-29
US20230017958A1 (en) 2023-01-19
EP4088725A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
MY197236A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
MX2017011386A (es) NUCLEÓTIDOS DE PURINA ß-D-2'-DEOXI-2'A-FLUORO-2'-ß-C-SUSTITUIDOS-2 - MODIFICADOS-N6- SUSTITUIDOS PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITIS C.
MX376106B (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b.
MX2022005899A (es) Moduladores de proteinas basicas de la hepatitis b.
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
HK1257628A1 (zh) 治療沙粒病毒科和冠狀病毒科病毒感染的方法
PH12018500263A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
PH12016500492A1 (en) Pyridazinone compounds and uses thereof
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
LT3999493T (lt) Aril-n-arilo dariniai, skirti rnr viruso infekcijos gydymui
HK40008711A (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
MY178600A (en) Antiviral composition against chikungunya virus